CytomX Therapeutics CTMX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $76.2M-44.8% | $138.1M+36.4% | $101.21M+90.4% | $53.16M+42.5% | ||
| $68.73M-17.6% | $83.38M+7.3% | $77.68M-30.4% | $111.65M-2.2% | ||
| $29.84M+0.4% | $29.73M-1.0% | $30.02M-29.9% | $42.85M+9.4% | ||
| $98.57M-12.9% | $113.11M+5.0% | $107.7M-30.3% | $154.5M+0.7% | ||
| $98.57M-12.9% | $113.11M+5.0% | $107.7M-30.3% | $154.5M+0.7% | ||
| -$22.37M-189% | $25M+485% | -$6.48M+93.6% | -$101.33M+12.7% | ||
| -29.4%-47.4pp | 18.1%+24.5pp | -6.4%+184pp | -190.6%+120pp | ||
| $5.21M-27.0% | $7.14M-27.5% | $9.84M+486% | $1.68M+558% | ||
| —— | -$39K— | —— | $340K+510% | ||
| -$17.13M-153% | $32.09M+866% | $3.32M+103% | -$99.32M+14.3% | ||
| $237K+6.3% | $223K-94.3% | $3.89M— | $0— | ||
| -$17.37M-154% | $31.87M— | —— | -$99.32M+14.3% | ||
| -22.8%-45.9pp | 23.1%— | —— | -186.8%+124pp | ||
| -$0.04-110% | $0.39— | —— | -$1.51+16.1% | ||
| -$0.04-110% | $0.39— | —— | -$1.51+16.1% | ||
| -$0.04-110% | $0.39— | —— | -$1.51+16.1% | ||
| 519.2M+53.8% | 337.5M+17.3% | 287.6M+9.5% | 262.6M+2.4% | ||
| 519.1M+54.3% | 336.4M+17.1% | 287.3M+9.4% | 262.6M+2.4% | ||
| -$0.04-110% | $0.39— | —— | -$1.51+16.1% | ||
| -$0.04-110% | $0.39— | —— | -$1.51+16.1% | ||
| -$17.28M-154% | $31.8M— | —— | -$99.06M+14.6% | ||
| -$3M— | $0— | —— | —— | ||
| $84K+224% | -$68K-180% | $85K-66.3% | $252K+229% | ||
| —— | -$39K— | —— | $340K+510% | ||
| $76.2M-44.8% | $138.1M+36.4% | $101.21M+90.4% | $53.16M+42.5% | ||
| -$22.37M-189% | $25M+485% | -$6.48M+93.6% | -$101.33M+12.7% | ||
| -$22.22M-188% | $25.14M+497% | -$6.34M+93.7% | -$101.19M+12.7% | ||
| -$22.22M-188% | $25.14M+497% | -$6.34M+93.7% | -$101.19M+12.7% | ||
| -29.2%-47.4pp | 18.2%+24.5pp | -6.3%+184pp | -190.3%+120pp | ||
| -$22.37M-189% | $25M+485% | -$6.48M+93.6% | -$101.33M+12.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is CytomX Therapeutics's revenue?
- CytomX Therapeutics (CTMX) generated $35.5M in revenue over the trailing twelve months, down 75.9% year over year.
- Is CytomX Therapeutics profitable?
- CytomX Therapeutics is not currently profitable: it reported a net loss of $59.1M over the trailing twelve months, a -166.4% net margin.
- What is CytomX Therapeutics's earnings per share?
- CytomX Therapeutics's diluted EPS over the trailing twelve months is $-0.41.
- Where does CytomX Therapeutics's income statement data come from?
- Every line is extracted from CytomX Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
